Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02413255 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT02413255 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 120 participants.
The verdict
NCT02413255, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ascending single- and multiple-doses of TAK-020 in healthy participants.
Interventions
- DRUG TAK-020
- DRUG TAK-020 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2015-03-18 |
| Est. Completion | 2017-05-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02413255
The ClinicalTrials.gov registry entry for NCT02413255 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-020 is the first listed.
NCT02413255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02413255 about?
NCT02413255 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ascending single- and multiple-doses of TAK-020 in healthy participants.
What is the current status of trial NCT02413255?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2015-03-18. Estimated completion is 2017-05-04.
What interventions are being tested in trial NCT02413255?
The interventions under investigation include: TAK-020 (DRUG), TAK-020 Placebo (DRUG).
Who is sponsoring clinical trial NCT02413255?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.